269055-15-4 | benzonitrile,4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-

Packsize	Purity	Availability	Price	Discounted Price
5mg	95%	in stock	$14.00	$10.00
10mg	95%	in stock	$25.00	$17.00
50mg	95%	in stock	$30.00	$21.00
100mg	95%	in stock	$38.00	$26.00
250mg	95%	in stock	$66.00	$46.00
1g	95%	in stock	$195.00	$136.00
5g	95%	in stock	$585.00	$409.00

Description

• Catalog Number: AI67621
• Chemical Name: benzonitrile,4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-
• CAS Number: 269055-15-4
• Molecular Formula: C20H15BrN6O
• Molecular Weight: 435.2767
• MDL Number: MFCD09837879
• SMILES: N#Cc1ccc(cc1)Nc1nc(N)c(c(n1)Oc1c(C)cc(cc1C)C#N)Br

Computed Properties

• Complexity: 609
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 4
• XLogP3: 4.5

Literature

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.

  Bioorganic & medicinal chemistry 20140615

• Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach.

  European journal of medicinal chemistry 20140610

• Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.

  Bioorganic & medicinal chemistry 20140415

• Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.

  European journal of medicinal chemistry 20140409

• Competitive fitness assays indicate that the E138A substitution in HIV-1 reverse transcriptase decreases in vitro susceptibility to emtricitabine.

  Antimicrobial agents and chemotherapy 20140401

• Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.

  Bioorganic & medicinal chemistry 20140401

• Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.

  Bioorganic & medicinal chemistry 20140315

• In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

  Antimicrobial agents and chemotherapy 20140301

• Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.

  Bioorganic & medicinal chemistry letters 20140201

• Evaluation of chitosan nanoformulations as potent anti-HIV therapeutic systems.

  Biochimica et biophysica acta 20140101

• Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.

  Bioorganic & medicinal chemistry 20140101

• Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect.

  AIDS research and human retroviruses 20131101

• In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

  Antimicrobial agents and chemotherapy 20131101

• Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.

  Bioorganic & medicinal chemistry 20131101

• Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.

  Bioorganic & medicinal chemistry letters 20130915

• Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.

  Bioorganic & medicinal chemistry 20130401

• DB-02, a C-6-cyclohexylmethyl substituted pyrimidinone HIV-1 reverse transcriptase inhibitor with nanomolar activity, displays an improved sensitivity against K103N or Y181C than S-DABOs.

  PloS one 20130101

• Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.

  Journal of medicinal chemistry 20121213

• Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.

  European journal of medicinal chemistry 20121201

• Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.

  The Journal of antimicrobial chemotherapy 20121101

• Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.

  Antimicrobial agents and chemotherapy 20121101

• Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.

  Journal of acquired immune deficiency syndromes (1999) 20121001

• Immune recovery and T cell subset analysis during effective treatment with maraviroc.

  The Journal of antimicrobial chemotherapy 20121001

• Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.

  The Journal of antimicrobial chemotherapy 20121001

• Antiretroviral neurotoxicity.

  Journal of neurovirology 20121001

• Etravirine: a guide to its use in treatment-experienced pediatric patients with HIV-1 infection in the US.

  Paediatric drugs 20121001

• Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.

  AIDS (London, England) 20120910

• High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs.

  The Journal of antimicrobial chemotherapy 20120901

• Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120901

• E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure.

  AIDS (London, England) 20120824

• Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens.

  AIDS (London, England) 20120824

• Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.

  Journal of medicinal chemistry 20120823

• Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest.

  HIV medicine 20120801

• From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.

  Journal of pharmacokinetics and pharmacodynamics 20120801

• New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.

  Journal of medicinal chemistry 20120726

• Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.

  European journal of medicinal chemistry 20120701

• Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.

  International journal of STD & AIDS 20120701

• Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.

  Bioorganic & medicinal chemistry 20120615

• Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience.

  AIDS research and human retroviruses 20120601

• Etravirine concentrations in CSF in HIV-infected patients.

  The Journal of antimicrobial chemotherapy 20120601

• Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen.

  The Journal of antimicrobial chemotherapy 20120601

• H2O2 signals via iron induction of VL30 retrotransposition correlated with cytotoxicity.

  Free radical biology & medicine 20120515

• Supersaturation in human gastric fluids.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20120501

• Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.

  European journal of medicinal chemistry 20120501

• Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection.

  Drugs 20120416

• Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.

  Journal of acquired immune deficiency syndromes (1999) 20120415

• [Leucoencephalopathy in a patient with type I human immunodeficiency virus (HIV-1) infection and symptoms of a hypertensive emergency].

  Enfermedades infecciosas y microbiologia clinica 20120401

• Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism.

  Drug metabolism and disposition: the biological fate of chemicals 20120401

• Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.

  Journal of medical virology 20120401

• Week 96 outcomes of patients with less treatment experience versus more treatment experience receiving etravirine in the DUET trials.

  Current HIV research 20120401

• HIV drug resistance interpreted by cumulative versus last genotypes in HIV-infected patients with multiple treatment failures.

  Current HIV research 20120401

• [Reverse transcriptase inhibitors, protease inhibitors].

  Nihon rinsho. Japanese journal of clinical medicine 20120401

• Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.

  AIDS (London, England) 20120327

• Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials.

  HIV medicine 20120301

• Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients.

  The Journal of antimicrobial chemotherapy 20120301

• Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.

  The Journal of antimicrobial chemotherapy 20120301

• Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents.

  AIDS (London, England) 20120220

• Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection.

  Pharmacotherapy 20120201

• Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.

  AIDS (London, England) 20120128

• The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.

  HIV medicine 20120101

• Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20120101

• [Safety and effectiveness of salvage therapy in HIV patients].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20120101

• Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.

  Antiviral therapy 20120101

• A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy.

  Antiviral therapy 20120101

• Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.

  HIV/AIDS (Auckland, N.Z.) 20120101

• Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa.

  PloS one 20120101

• HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone.

  PloS one 20120101

• Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.

  HIV clinical trials 20120101

• Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.

  AIDS research and treatment 20120101

• Impact of Novel Resistance Profiles in HIV-1 Reverse Transcriptase on Phenotypic Resistance to NVP.

  AIDS research and treatment 20120101

• New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.

  HIV/AIDS (Auckland, N.Z.) 20120101

• Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.

  PloS one 20120101

• Antiretroviral drugs: critical issues and recent advances.

  Indian journal of pharmacology 20120101

• Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.

  Journal of medicinal chemistry 20111222

• Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.

  ChemMedChem 20111209

• Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States.

  AIDS research and human retroviruses 20111201

• Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.

  Bioorganic & medicinal chemistry 20111201

• Emerging trends of drug-resistant HIV-1 among drug-treated patients in former blood donors in Hubei, China: a three-year surveillance from 2004 to 2006.

  Virologica Sinica 20111201

• Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.

  Current HIV research 20111201

• Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?

  The Indian journal of medical research 20111201

• Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.

  AIDS (London, England) 20111128

• Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.

  Drugs 20111112

• In vitro activity of antiretroviral drugs against Plasmodium falciparum.

  Antimicrobial agents and chemotherapy 20111101

• HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.

  Antiviral research 20111101

• Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20111101

• Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.

  Journal of medical virology 20111001

• Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.

  European journal of medicinal chemistry 20111001

• Resistance-associated mutation prevalence according to subtypes B and non-B of HIV type 1 in antiretroviral-experienced patients in Minas Gerais, Brazil.

  AIDS research and human retroviruses 20110901

• Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine.

  Journal of acquired immune deficiency syndromes (1999) 20110901

• Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.

  Bioorganic & medicinal chemistry 20110901

• A computational study of CYP3A4 mediated drug interaction profiles for anti-HIV drugs.

  Journal of molecular modeling 20110801

• Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients.

  HIV medicine 20110801

• Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.

  The Journal of antimicrobial chemotherapy 20110801

• Prevalence of etravirine-associated mutations in clinical samples with genotypic resistance to nevirapine and efavirenz in Brazilian clinics.

  Journal of acquired immune deficiency syndromes (1999) 20110801

• Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.

  AIDS research and human retroviruses 20110701

• Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.

  The Journal of antimicrobial chemotherapy 20110701

• Resistance to antiretroviral drugs in treated and drug-naive patients in the Democratic Republic of Congo.

  Journal of acquired immune deficiency syndromes (1999) 20110701

• Endothelial, inflammatory, coagulation, metabolic effects and safety of etravirine in HIV-uninfected volunteers.

  AIDS patient care and STDs 20110601

• Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance.

  AIDS (London, England) 20110515

• HIV-1 integrase inhibitor resistance and its clinical implications.

  The Journal of infectious diseases 20110501

• [Characteristics of antiretroviral drugs].

  Enfermedades infecciosas y microbiologia clinica 20110501

• Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.

  Bioanalysis 20110501

• CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope.

  PLoS pathogens 20110501

• Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'.

  AIDS (London, England) 20110424

• Excipient-mediated supersaturation stabilization in human intestinal fluids.

  Molecular pharmaceutics 20110404

• Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.

  Antimicrobial agents and chemotherapy 20110401

• Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.

  Journal of acquired immune deficiency syndromes (1999) 20110401

• Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women.

  HIV medicine 20110401

• Clinical management of HIV drug resistance.

  Viruses 20110401

• A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.

  Journal of pharmaceutical and biomedical analysis 20110325

• Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide.

  Journal of medicinal chemistry 20110324

• Atomic force microscopy-based screening of drug-excipient miscibility and stability of solid dispersions.

  Pharmaceutical research 20110301

• Levels of adherence required for virologic suppression among newer antiretroviral medications.

  The Annals of pharmacotherapy 20110301

• Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.

  AIDS (London, England) 20110220

• Theoretical studies on the molecular basis of HIV-1RT/NNRTIs interactions.

  Journal of enzyme inhibition and medicinal chemistry 20110201

• Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20110201

• HIV-1 drug resistance testing from dried blood spots collected in rural Tanzania using the ViroSeq HIV-1 Genotyping System.

  The Journal of antimicrobial chemotherapy 20110201

• Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.

  The Journal of antimicrobial chemotherapy 20110201

• Recent FDA approvals and changes.

  AIDS patient care and STDs 20110201

• A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.

  AIDS (London, England) 20110128

• SENSE makes us rethink the second-generation nonnucleoside reverse transcriptase inhibitor etravirine's place in HIV-1 treatment.

  AIDS (London, England) 20110128

• A randomized crossover study to compare efavirenz and etravirine treatment.

  AIDS (London, England) 20110102

• A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.

  AIDS (London, England) 20110102

• Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: etravirine.

  Journal of pharmaceutical sciences 20110101

• Recent advances in antiretroviral drugs.

  Expert opinion on pharmacotherapy 20110101

• Pharmacokinetic interactions between etravirine and non-antiretroviral drugs.

  Clinical pharmacokinetics 20110101

• Recent advances in DAPYs and related analogues as HIV-1 NNRTIs.

  Current medicinal chemistry 20110101

• Indications for the use of next-generation antiretroviral drugs in current clinical practice.

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20110101

• Human Herpesvirus-8 Infection Associated with Kaposi Sarcoma, Multicentric Castleman's Disease, and Plasmablastic Microlymphoma in a Man with AIDS: A Case Report with Review of Pathophysiologic Processes.

  Pathology research international 20110101

• Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study.

  Journal of translational medicine 20110101

• Clinical use of CCR5 inhibitors in HIV and beyond.

  Journal of translational medicine 20110101

• A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa.

  Journal of the International AIDS Society 20110101

• HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL.

  Lipids in health and disease 20110101

• 'Dynamic range' of inferred phenotypic HIV drug resistance values in clinical practice.

  PloS one 20110101

• The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients.

  AIDS reviews 20110101

• Use of maraviroc-, raltegravir-, and etravirine-containing regimens in treatment-experienced patients: a case-series study.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20110101

• HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients.

  Virology journal 20110101

• Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial.

  PloS one 20110101

• Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.

  AIDS research and treatment 20110101

• Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa.

  AIDS research and treatment 20110101

• Identification of new, emerging HIV-1 unique recombinant forms and drug resistant viruses circulating in Cameroon.

  Virology journal 20110101

• The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.

  Retrovirology 20110101

• Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina.

  Enfermedades infecciosas y microbiologia clinica 20110101

• Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis.

  Malaria journal 20110101

• Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.

  PloS one 20110101

• Safety and tolerability of antiretrovirals during pregnancy.

  Infectious diseases in obstetrics and gynecology 20110101

• A synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assay.

  PloS one 20110101

• Contraception in HIV-positive female adolescents.

  AIDS research and therapy 20110101

• HIV and HAART-Associated Dyslipidemia.

  The open cardiovascular medicine journal 20110101

• High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo.

  Journal of the International AIDS Society 20110101

• Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.

  HIV clinical trials 20110101

• Surveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, Zimbabwe.

  PloS one 20110101

• The HIV-1 Rev/RRE system is required for HIV-1 5' UTR cis elements to augment encapsidation of heterologous RNA into HIV-1 viral particles.

  Retrovirology 20110101

• Human immunodeficiency virus infection and autoimmune hepatitis during highly active anti-retroviral treatment: a case report and review of the literature.

  Journal of medical case reports 20110101

• Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.

  PloS one 20110101

• Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.

  Patient preference and adherence 20110101

• Prevention of perinatal HIV transmission: the Perinatal HIV Hotline perspective.

  Topics in antiviral medicine 20110101

• Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?

  PloS one 20110101

• Nephrotoxicity of HAART.

  AIDS research and treatment 20110101

• HIV-Associated Venous Thromboembolism.

  Mediterranean journal of hematology and infectious diseases 20110101

• Health-related quality of life in the gender, race, and clinical experience trial.

  AIDS research and treatment 20110101

• Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations.

  BMC bioinformatics 20110101

• A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries.

  Globalization and health 20110101

• Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.

  Antiviral therapy 20110101

• Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population.

  PloS one 20110101

• It is time to consider third-line options in antiretroviral-experienced paediatric patients?

  Journal of the International AIDS Society 20110101

• Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Role of raltegravir in the management of HIV-1 infection.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

  PloS one 20110101

• Which compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical development.

  PloS one 20110101

• Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).

  Antiviral therapy 20110101

• Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.

  Antiviral therapy 20110101

• Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease.

  BMC infectious diseases 20110101

• Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals.

  Malaria research and treatment 20110101

• Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.

  Acta naturae 20110101

• Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.

  Journal of medicinal chemistry 20101209

• Pharmacokinetic evaluation of etravirine.

  Expert opinion on drug metabolism & toxicology 20101201

• Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism.

  Pharmacogenetics and genomics 20101201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20101201

• Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.

  Viruses 20101201

• Update of the drug resistance mutations in HIV-1: December 2010.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20101201

• A report from the XVIII International AIDS Conference. (July 18-23, 2010-Vienna, Austria).

  Drugs of today (Barcelona, Spain : 1998) 20101201

• LC-MS/MS determination of etravirine in rat plasma and its application in pharmacokinetic studies.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20101115

• Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.

  AIDS (London, England) 20101113

• Raltegravir-induced cerebellar ataxia.

  AIDS (London, England) 20101113

• Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.

  The Journal of antimicrobial chemotherapy 20101101

• Drug supersaturation in simulated and human intestinal fluids representing different nutritional states.

  Journal of pharmaceutical sciences 20101101

• Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.

  The Journal of antimicrobial chemotherapy 20101101

• Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.

  AIDS research and human retroviruses 20101101

• Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.

  Clinical pharmacology and therapeutics 20101101

• A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).

  AIDS research and human retroviruses 20101101

• Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.

  International journal of STD & AIDS 20101101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20101101

• Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.

  Viruses 20101101

• Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.

  AIDS (London, England) 20101023

• Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.

  Bioorganic & medicinal chemistry letters 20101015

• HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

  HIV medicine 20101001

• Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.

  Antimicrobial agents and chemotherapy 20101001

• Naturally occurring polymorphisms and primary drug resistance profile among antiretroviral-naive individuals in Bangalore, India.

  AIDS research and human retroviruses 20101001

• Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.

  Current HIV research 20101001

• Pharmacoeconomics of etravirine.

  Expert review of pharmacoeconomics & outcomes research 20101001

• Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

  Drugs 20100910

• HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions.

  Journal of pharmaceutical and biomedical analysis 20100905

• Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA).

  HIV medicine 20100901

• Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots.

  Analytical and bioanalytical chemistry 20100901

• Cyanation of arenes via iridium-catalyzed borylation.

  Journal of the American Chemical Society 20100825

• Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.

  Antiviral chemistry & chemotherapy 20100811

• A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry.

  Clinical chemistry and laboratory medicine 20100801

• Methadone, buprenorphine, and street drug interactions with antiretroviral medications.

  Current HIV/AIDS reports 20100801

• Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses.

  Bioorganic & medicinal chemistry letters 20100715

• Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.

  Bioorganic & medicinal chemistry 20100715

• Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.

  Journal of medicinal chemistry 20100708

• Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.

  The Journal of antimicrobial chemotherapy 20100701

• A review of the safety and tolerability profile of the next-generation NNRTI etravirine.

  AIDS research and human retroviruses 20100701

• Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.

  Expert opinion on pharmacotherapy 20100601

• Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100601

• Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.

  AIDS research and human retroviruses 20100601

• Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine.

  AIDS research and human retroviruses 20100601

• Colloid formation by drugs in simulated intestinal fluid.

  Journal of medicinal chemistry 20100527

• Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design.

  Journal of medicinal chemistry 20100527

• In vitro resistance development for RO-0335, a novel diphenylether nonnucleoside reverse transcriptase inhibitor.

  Antiviral research 20100501

• FDA notifications. Etravirine label updated by FDA.

  AIDS alert 20100501

• Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.

  British journal of clinical pharmacology 20100501

• A rare case of severe myopathy associated with etravirine use.

  AIDS (London, England) 20100424

• Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.

  Journal of acquired immune deficiency syndromes (1999) 20100401

• Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1.

  Current HIV research 20100401

• Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20100401

• Recent FDA approvals and changes.

  AIDS patient care and STDs 20100401

• HIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide Substrate.

  Viruses 20100401

• Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.

  AIDS (London, England) 20100327

• Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials.

  AIDS (London, England) 20100327

• Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100315

• Impact of human leukocyte antigen-B*51-restricted cytotoxic T-lymphocyte pressure on mutation patterns of nonnucleoside reverse transcriptase inhibitor resistance.

  AIDS (London, England) 20100313

• HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.

  International journal of STD & AIDS 20100301

• Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20100301

• N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.

  Bioorganic & medicinal chemistry letters 20100301

• N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.

  Bioorganic & medicinal chemistry letters 20100301

• HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil.

  AIDS research and human retroviruses 20100301

• Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials.

  AIDS research and human retroviruses 20100301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100301

• Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.

  AIDS (London, England) 20100220

• TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

  Antimicrobial agents and chemotherapy 20100201

• Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.

  The Journal of antimicrobial chemotherapy 20100201

• Etravirine: A novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100201

• Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.

  Clinical therapeutics 20100201

• HIV treatment information.

  Project Inform perspective 20100201

• [Discovery and development of diarylpyrimidines (DAPYs) as next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)].

  Yao xue xue bao = Acta pharmaceutica Sinica 20100201

• [Establishment and application of a high-throughput screening assay for premature activation of HIV-1 precursors].

  Yao xue xue bao = Acta pharmaceutica Sinica 20100201

• Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database.

  AIDS (London, England) 20100128

• [Pharmacovigilance update].

  Revue medicale suisse 20100120

• Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs.

  AIDS (London, England) 20100116

• N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.

  AIDS (London, England) 20100116

• An investigation into the crystallisation behaviour of an amorphous cryomilled pharmaceutical material above and below the glass transition temperature.

  Journal of pharmaceutical sciences 20100101

• Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.

  Antiviral research 20100101

• Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).

  Antiviral research 20100101

• Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.

  The Annals of pharmacotherapy 20100101

• Drug interactions with new and investigational antiretrovirals.

  Clinical pharmacokinetics 20100101

• Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test.

  Journal of acquired immune deficiency syndromes (1999) 20100101

• One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India.

  AIDS research and human retroviruses 20100101

• Towards a Patent Pool for HIV Medicines: The Background.

  The open AIDS journal 20100101

• Pooling ARV Drug Patents: A Pro-Access Fitting Strategy?

  The open AIDS journal 20100101

• Profile of etravirine for the treatment of HIV infection.

  Therapeutics and clinical risk management 20100101

• Designing ARVs Patent Pool Up to Trade & Policy Evolutionary Dynamics.

  The open AIDS journal 20100101

• Simplification of antiretroviral therapy with etravirine.

  AIDS reviews 20100101

• Decreased NK Cell FcRgamma in HIV-1 infected individuals receiving combination antiretroviral therapy: a cross sectional study.

  PloS one 20100101

• Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials.

  HIV clinical trials 20100101

• The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.

  PloS one 20100101

• Recent key advances in human immunodeficiency virus medicine and implications for China.

  AIDS research and therapy 20100101

• Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.

  Antiviral therapy 20100101

• Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time.

  PloS one 20100101

• High performance liquid chromatography using UV detection for the simultaneous quantification of the new non-nucleoside reverse transcriptase inhibitor etravirine (TMC-125), and 4 protease inhibitors in human plasma.

  Biological & pharmaceutical bulletin 20100101

• Case report: HIV infection from a kidney transplant.

  Transplantation proceedings 20100101

• Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.

  European journal of medical research 20100101

• Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.

  Antiviral therapy 20100101

• From bench to clinic: accessing promising investigational medications for patients with HIV infection in an urban family health center.

  Journal of the American Board of Family Medicine : JABFM 20100101

• Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance.

  Antiviral therapy 20100101

• Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.

  Antiviral therapy 20100101

• Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen.

  Clinical epidemiology 20100101

• Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C.

  Retrovirology 20100101

• Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.

  Retrovirology 20100101

• The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children.

  BMC pediatrics 20100101

• Genotypic evaluation of etravirine sensitivity of clinical human immunodeficiency virus type 1 (HIV-1) isolates carrying resistance mutations to nevirapine and efavirenz.

  Acta clinica Belgica 20100101

• Progress in antiretroviral drug delivery using nanotechnology.

  International journal of nanomedicine 20100101

• Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2.

  HIV clinical trials 20100101

• Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.

  Antiviral therapy 20100101

• Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models.

  PloS one 20100101

• Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution.

  AIDS research and therapy 20100101

• Mutations in the C-terminal region of the HIV-1 reverse transcriptase and their correlation with drug resistance associated mutations and antiviral treatment.

  European journal of medical research 20100101

• Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009.

  PloS one 20100101

• Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.

  PharmacoEconomics 20100101

• Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.

  Cholesterol 20100101

• Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection.

  Infection and drug resistance 20100101

• Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy.

  Infection and drug resistance 20100101

• Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Long-term treatment of patients with HIV-1: the role of atazanavir.

  HIV/AIDS (Auckland, N.Z.) 20100101

• The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?

  Clinical pharmacology : advances and applications 20100101

• Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme.

  The Journal of antimicrobial chemotherapy 20091201

• Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.

  Therapeutic drug monitoring 20091201

• Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure.

  The Pediatric infectious disease journal 20091201

• Will etravirine work in patients failing nonnucleoside reverse transcriptase inhibitor-based treatment in southern Africa?

  Journal of acquired immune deficiency syndromes (1999) 20091201

• [Introduction. Etravirine: a new standard of potency and safety among non-nucleoside analogues].

  Enfermedades infecciosas y microbiologia clinica 20091201

• [Chemical characteristics, mechanism of action and antiviral activity of etravirine].

  Enfermedades infecciosas y microbiologia clinica 20091201

• [Etravirine in highly treatment-experienced patients].

  Enfermedades infecciosas y microbiologia clinica 20091201

• [Etravirine in first-line therapy].

  Enfermedades infecciosas y microbiologia clinica 20091201

• [Safety and tolerability of etravirine].

  Enfermedades infecciosas y microbiologia clinica 20091201

• [Etravirine drug interactions].

  Enfermedades infecciosas y microbiologia clinica 20091201

• [Etravirine: genetic barrier and resistance development].

  Enfermedades infecciosas y microbiologia clinica 20091201

• [Etravirine in special populations].

  Enfermedades infecciosas y microbiologia clinica 20091201

• [Role of etravirine in combination antiretroviral therapy].

  Enfermedades infecciosas y microbiologia clinica 20091201

• Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.

  AIDS (London, England) 20091113

• Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.

  AIDS (London, England) 20091113

• Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

  Journal of acquired immune deficiency syndromes (1999) 20091101

• Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).

  HIV medicine 20091101

• Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.

  Journal of acquired immune deficiency syndromes (1999) 20091101

• Efavirenz: a decade of clinical experience in the treatment of HIV.

  The Journal of antimicrobial chemotherapy 20091101

• High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20091101

• First-line regimen failure of antiretroviral therapy: a clinical and evidence-based approach.

  Current opinion in HIV and AIDS 20091101

• Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).

  Current opinion in HIV and AIDS 20091101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20091101

• A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma.

  Talanta 20091015

• Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20091001

• New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.

  Expert opinion on pharmacotherapy 20091001

• [Pharmacological and clinical profile of Etravirine (Intelence)].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20091001

• Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain.

  AIDS research and human retroviruses 20091001

• FDA notifications. Dear Healthcare letter for etravirine.

  AIDS alert 20091001

• Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.

  Bioorganic & medicinal chemistry letters 20090915

• New developments in HIV drug resistance.

  The Journal of antimicrobial chemotherapy 20090901

• The history of antiretrovirals: key discoveries over the past 25 years.

  Reviews in medical virology 20090901

• [Etravirine--oral administration (Intelence)].

  Journal de pharmacie de Belgique 20090901

• Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.

  Medical microbiology and immunology 20090801

• Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples.

  AIDS (London, England) 20090731

• Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone.

  Contraception 20090701

• Etravirine plasma levels in a patient with decompensated liver disease.

  AIDS (London, England) 20090619

• Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.

  Antimicrobial agents and chemotherapy 20090601

• Etravirine: new drug. Multidrug-resistant HIV: another option.

  Prescrire international 20090601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090501

• Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases.

  AIDS (London, England) 20090427

• Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090415

• A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090415

• Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

  International journal of antimicrobial agents 20090401

• Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.

  Journal of medical virology 20090401

• Johnson & Johnson seeks full FDA approval for Intelence.

  The AIDS reader 20090401

• Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.

  Clinical therapeutics 20090401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090401

• Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on haemodialysis.

  AIDS (London, England) 20090327

• Efficacy of etravirine for treatment of acute HIV meningoencephalitis.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090315

• Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.

  HIV medicine 20090301

• Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.

  Pharmacotherapy 20090301

• The fusion inhibitor enfuvirtide in recent antiretroviral strategies.

  Current opinion in HIV and AIDS 20090301

• Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mononuclear cell lysate by liquid chromatography tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20090220

• Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.

  Journal of medicinal chemistry 20090212

• Pharmacologic aspects of new antiretroviral drugs.

  Current HIV/AIDS reports 20090201

• Warfarin-antiretroviral interactions.

  The Annals of pharmacotherapy 20090201

• Raltegravir and etravirine are active against HIV type 1 group O.

  AIDS research and human retroviruses 20090201

• Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial.

  AIDS (London, England) 20090128

• Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance.

  AIDS (London, England) 20090128

• Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

  PloS one 20090101

• Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child.

  PloS one 20090101

• Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.

  AIDS reviews 20090101

• Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection.

  European journal of medical research 20090101

• Role of atazanavir in the treatment of HIV infection.

  Therapeutics and clinical risk management 20090101

• Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.

  Antiviral therapy 20090101

• Drug interactions with new and investigational antiretrovirals.

  Clinical pharmacokinetics 20090101

• Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use.

  PloS one 20090101

• Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008).

  Journal of the International AIDS Society 20090101

• Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs.

  BMC infectious diseases 20090101

• HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.

  AIDS reviews 20090101

• Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study.

  Retrovirology 20090101

• Pharmacotherapy of pediatric and adolescent HIV infection.

  Therapeutics and clinical risk management 20090101

• Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.

  Therapeutics and clinical risk management 20090101

• Clinical pharmacokinetics and pharmacodynamics of etravirine.

  Clinical pharmacokinetics 20090101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090101

• Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens.

  Journal of the International AIDS Society 20090101

• Etravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.

  Retrovirology 20090101

• Progress in basic and clinical research on HIV resistance: report on the XVIII International HIV Drug Resistance Workshop.

  Antiviral therapy 20090101

• Two standards of care for HIV: why are Africans being short-changed?

  Retrovirology 20090101

• A Rough Set-Based Model of HIV-1 Reverse Transcriptase Resistome.

  Bioinformatics and biology insights 20090101

• Canadian consensus guidelines for the optimal use of etravirine in the treatment of HIV-infected adults.

  The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale 20090101

• Raltegravir: The evidence of its therapeutic value in HIV-1 infection.

  Core evidence 20090101

• Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection.

  Core evidence 20090101

• Profile of darunavir in the management of treatment-experienced HIV patients.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.

  Journal of medicinal chemistry 20081211

• An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients.

  Therapeutic drug monitoring 20081201

• Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.

  Expert opinion on pharmacotherapy 20081201

• No hepatotoxicity found for etravirine.

  AIDS patient care and STDs 20081201

• Two studies look at Intelence.

  Project Inform perspective 20081201

• Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues.

  AIDS (London, England) 20081112

• Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.

  The Journal of antimicrobial chemotherapy 20081101

• Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection.

  The Journal of antimicrobial chemotherapy 20081101

• Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.

  HIV medicine 20081101

• Pharmacologic aspects of new antiretroviral drugs.

  Current infectious disease reports 20081101

• Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.

  AIDS patient care and STDs 20081101

• [Role of the new molecules in antiretroviral therapy. Position of raltegravir].

  Enfermedades infecciosas y microbiologia clinica 20081101

• A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers.

  British journal of clinical pharmacology 20081001

• Shifting paradigms: the resistance profile of etravirine.

  The Journal of antimicrobial chemotherapy 20081001

• Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20081001

• Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.

  Pharmacotherapy 20081001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20081001

• [Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Resistance to darunavir].

  Enfermedades infecciosas y microbiologia clinica 20081001

• Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006.

  The Journal of antimicrobial chemotherapy 20080901

• A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

  Antiviral research 20080901

• Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting.

  Current HIV research 20080901

• HIV infection in the elderly.

  Clinical interventions in aging 20080901

• Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

  JAMA 20080806

• Follow-up of a multi-drug resistant HIV-1 infected patient successfully treated with darunavir and etravirine.

  Journal of medical virology 20080801

• Etravirine for the treatment of HIV infection.

  Expert review of anti-infective therapy 20080801

• Combating HIV resistance - focus on darunavir.

  Therapeutics and clinical risk management 20080801

• Combating Non-nucleoside Reverse Transcriptase Inhibitor Resistance with a Focus On Etravirine (Intelence) for HIV-1 Infection.

  P & T : a peer-reviewed journal for formulary management 20080801

• New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.

  The Journal of infection 20080701

• How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals.

  Drug discovery today 20080701

• Etravirine(Intelence) for HIV infection.

  The Medical letter on drugs and therapeutics 20080616

• Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.

  The Annals of pharmacotherapy 20080601

• Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection.

  AIDS patient care and STDs 20080601

• New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.

  Journal of HIV therapy 20080601

• Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?

  AIDS (London, England) 20080511

• Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: a single center analysis.

  Journal of medical virology 20080501

• Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs.

  AIDS patient care and STDs 20080501

• Complexity of interactions between voriconazole and antiretroviral agents.

  The Annals of pharmacotherapy 20080501

• Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV.

  Current opinion in HIV and AIDS 20080501

• Contraceptive patch: new labeling.

  Nursing for women's health 20080401

• Raltegravir: first in class HIV integrase inhibitor.

  Therapeutics and clinical risk management 20080401

• Report from the 15th Retrovirus Conference. Etravirine resistance: baseline prevalence and proposed criteria for 'vircotype'.

  AIDS clinical care 20080401

• Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers.

  Journal of clinical pharmacology 20080301

• 48-week data released for etravirine (TMC125).

  AIDS patient care and STDs 20080301

• FDA approval: etravirine.

  AIDS clinical care 20080301

• [New drugs for HIV infection].

  Revue de l'infirmiere 20080301

• FDA notifications. FDA grants accelerated approval for etravirine.

  AIDS alert 20080301

• 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.

  Bioorganic & medicinal chemistry letters 20080201

• FDA approves new HIV drug after priority review.

  AIDS patient care and STDs 20080201

• Hemorrhagic cardiomyopathy in male mice treated with an NNRTI: the role of vitamin K.

  Toxicologic pathology 20080201

• The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal.

  Retrovirology 20080101

• Etravirine.

  Drugs of today (Barcelona, Spain : 1998) 20080101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080101

• Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Advances in antiretroviral therapy.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20080101

• New drugs: Etravirine, sinecatechins, and desvenlafaxine succinate.

  Journal of the American Pharmacists Association : JAPhA 20080101

• Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.

  Antiviral therapy 20080101

• Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.

  Antiviral therapy 20080101

• Emerging resistance profiles of newly approved antiretroviral drugs.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20080101

• Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1.

  Antiviral therapy 20080101

• Etravirine.

  Drugs 20080101

• Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine.

  Antiviral therapy 20080101

• Broad advances in understanding HIV resistance to antiretrovirals: report on the XVII International HIV Drug Resistance Workshop.

  Antiviral therapy 20080101

• Raltegravir in the management of HIV-infected patients.

  Drug design, development and therapy 20080101

• Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors.

  The Journal of antimicrobial chemotherapy 20071201

• Resistance testing methodologies and mechanisms of resistance.

  Journal of HIV therapy 20071201

• From docking false-positive to active anti-HIV agent.

  Journal of medicinal chemistry 20071101

• Antiviral drugs in the treatment of AIDS: what is in the pipeline ?

  European journal of medical research 20071015

• FDA accepts NDA for priority review of TMC125.

  AIDS patient care and STDs 20071001

• Lessons Learned From 2 Patients With Multidrug-Resistant HIV-1 Infection Successfully Treated With a Darunavir-Containing Antiretroviral Treatment Regimen.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20070901

• NDA submitted for TMC125.

  AIDS patient care and STDs 20070901

• Report from the XVI International HIV Drug Resistance Workshop.

  AIDS clinical care 20070801

• Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.

  AIDS (London, England) 20070711

• No patient left behind--better treatments for resistant HIV infection.

  Lancet (London, England) 20070707

• Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

  Lancet (London, England) 20070707

• Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

  Lancet (London, England) 20070707

• Drug resistant HIV.

  BMJ (Clinical research ed.) 20070602

• Advances in HIV therapeutics: the 14th CROI.

  The AIDS reader 20070501

• Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.

  AIDS (London, England) 20070330

• TMC125 (etravirine), a second generation non-nucleoside reverse transcriptase inhibitor.

  AIDS alert 20070201

• Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs).

  Biochemical and biophysical research communications 20070112

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070101

• Anti-HIV agents. The need for etravirine (TMC125).

  TreatmentUpdate 20070101

• Anti-HIV agents. Etravirine--interactions with some medications.

  TreatmentUpdate 20070101

• Anti-HIV agents. Effectiveness of etravirine in treatment-experienced PHAs.

  TreatmentUpdate 20070101

• Anti-HIV agents. Brain side effects not common with etravirine.

  TreatmentUpdate 20070101

• Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial.

  HIV clinical trials 20070101

• Expanded drug access: etravirine (formerly TMC-125).

  The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20070101

• Antiretroviral treatment of HIV infection: Swedish recommendations 2007.

  Scandinavian journal of infectious diseases 20070101

• Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.

  Antiviral therapy 20070101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070101

• Clinical implications of mutations at reverse transcriptase codon 135 on response to NNRTI-based therapy.

  The open virology journal 20070101

• Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.

  Bioorganic & medicinal chemistry letters 20061101

• Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.

  PLoS pathogens 20061101

• British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

  HIV medicine 20061101

• TMC125 study highlights failing NNRTI regimen task.

  IAPAC monthly 20061101

• AIDS 2006 - XVI International Conference. Time to deliver.

  IDrugs : the investigational drugs journal 20061001

• The latest in antiretroviral therapy.

  Drug news & perspectives 20061001

• The clinical pharmacology of antiretrovirals in development.

  Expert opinion on drug metabolism & toxicology 20060601

• Report from the 13th retrovirus conference. New data on TMC114 and TMC125.

  AIDS clinical care 20060401

• Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.

  Bioorganic & medicinal chemistry letters 20060201

• Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.

  Current opinion in investigational drugs (London, England : 2000) 20060201

• Etravirine: R165335, TMC 125, TMC-125, TMC125.

  Drugs in R&D 20060101

• Drug interactions. Interactions with TMC114 and TMC125.

  TreatmentUpdate 20060101

• New drugs.

  HIV medicine 20050701

• Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors.

  Progress in biophysics and molecular biology 20050601

• The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.

  Journal of the American Chemical Society 20050525

• Emerging anti-HIV drugs.

  Expert opinion on emerging drugs 20050501

• From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.

  Journal of medicinal chemistry 20050324

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050101

• TMC125: new results, large phase III trial begins.

  AIDS treatment news 20050101

• TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

  Antimicrobial agents and chemotherapy 20041201

• New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections.

  Current opinion in pharmacology 20041001

• A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides.

  Antimicrobial agents and chemotherapy 20041001

• HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches.

  The international journal of biochemistry & cell biology 20040901

• Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: viral potency of chiral PETT derivatives.

  Biochemical pharmacology 20040515

• Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.

  Journal of medicinal chemistry 20040506

• TMC125: important one-year trial now recruiting in U.S.

  AIDS treatment news 20040430

• TMC-125 Tibotec.

  Current opinion in investigational drugs (London, England : 2000) 20040201

• TMC 125 possibly effective against NNRTI-resistant HIV.

  IAPAC monthly 20040101

• Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.

  Current topics in medicinal chemistry 20040101

• Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors.

  Current topics in medicinal chemistry 20040101

• Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compounds.

  Drugs in R&D 20040101

• Behind 'AIDS breakthrough' headlines, December 2004: important research, not so new.

  AIDS treatment news 20040101

• TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.

  AIDS (London, England) 20031205

• An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.

  AIDS (London, England) 20031205

• A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects.

  AIDS (London, England) 20031121

• Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125.

  Journal of the American Chemical Society 20030521

• One as potent as five.

  AIDS (London, England) 20020816

• Drugs in development.

  AIDS patient care and STDs 20020501

• Researchers explore new anti-HIV agents.

  JAMA 20020403

• Promising new agents on the horizon.

  AIDS clinical care 20020301

• Tests on new NNRTI show strong potency.

  AIDS alert 20020201

• TMC125 shows promise.

  AIDS patient care and STDs 20020201

• Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.

  Bioorganic & medicinal chemistry letters 20010903